secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0000950170-23-059753
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics Q3 2023: net loss $24M, Phase 3 enrollment complete, cash runway extended into 2026
--------------------------------------------------------------------------------

- Completed enrollment in Phase 3 REACH trial of losmapimod for FSHD; topline data expected Q4 2024.
- FDA lifted clinical hold for pociredir in sickle cell disease; Phase 1b trial reinitiation underway with amended protocol.
- Net loss of $24.0M for Q3 2023 vs $23.7M in prior-year quarter; R&D expenses increased to $18.2M.
- Cash, cash equivalents, and marketable securities $257.1M as of Sep 30, 2023; cash runway extended into 2026.
- Collaboration revenue $0.8M, down from $1.2M in Q3 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000095017023059753/0000950170-23-059753-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000095017023059753/fulc-20231107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-059753

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer